Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Clearmind Medicine

Tracked across 2 events · 13 articles · First seen Jun 18, 2026 · Last active Aug 13, 2026

Sentiment
70
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 70
Business
Impact: Clearmind Medicine received two U.S. patents, strengthening its intellectual property portfolio for binge behavior regulators and advancing its clinical programs for related disorders. This enhances the company's market position and potential for commercialization.
Jun 18, 2026 · 7 articles
2 70
Business
Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotech company, announced that its independent Data and Safety Monitoring Board (DSMB) unanimously approved advancing its FDA-regulated Phase I/II clinical trial of CMND-100, a non-hallucinogenic neuroplastogen-derived candidate for…
Impact: Clearmind is the sponsor of the trial and the primary beneficiary of the DSMB approval, which advances its lead candidate CMND-100 into patient testing and supports its clinical development program.
Aug 06, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Clearmind Medicine live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.